FDA 483 - Lupin Limited - September 18, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Lupin Limited, a drug product manufacturer in Verna, Goa, India, received a Form 483 with seven observations. The inspection revealed significant deficiencies in quality control, including inadequate investigations into discrepancies, insufficient in-process material testing, and a failure to validate component supplier test results. Additionally, issues were noted with annual product reviews not including returned products, non-adherence to stability programs, and uncontrolled access to labeling materials.
ID · 43a586e1-9912-4c60-bdbe-09e846247eb3